Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 11 2020 - 05:30PM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical
company focused on the development and commercialization of a
late-stage pipeline of novel therapies for debilitating liver
diseases, today announced that the Compensation Committee of
Mirum’s Board of Directors granted a non-qualified stock option
award to purchase an aggregate of 25,000 shares of common stock to
one new employee under Mirum’s 2020 Inducement Plan. The
Compensation Committee of Mirum’s Board of Directors approved the
awards as an inducement material to the new employee’s employment
in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to
$26.59 per share, Mirum’s closing trading price on August 10, 2020,
and will vest over four years, with 25% of the underlying shares
vesting on the one-year anniversary of the applicable vesting
commencement date and the balance of the underlying shares vesting
monthly thereafter over 36 months, subject to the new employee's
continued service relationship with Mirum through the applicable
vesting dates. The award is subject to the terms and conditions of
Mirum’s 2020 Inducement Plan and the terms and conditions of an
applicable award agreement covering the grant.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a late-stage pipeline of novel therapies for
debilitating liver diseases. The company’s lead product candidate,
maralixibat, is an investigational oral drug in development for
Alagille syndrome (ALGS) and progressive familial intrahepatic
cholestasis (PFIC). For more information, visit MirumPharma.com.
Follow Mirum on Twitter, Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200811005685/en/
Investor Contact: Ian Clements, Ph.D.
ir@mirumpharma.com
Media Contact: Erin Murphy media@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Mar 2023 to Mar 2024